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Molecular mechanisms remain unknown for most type 2
diabetes genome-wide association study identified loci.
Variants associated with type 2 diabetes and fasting
glucose levels reside in introns of ADCY5, a gene that
encodes adenylate cyclase 5. Adenylate cyclase 5 cata-
lyzes the production of cyclic AMP, which is a second
messenger molecule involved in cell signaling and pan-
creatic b-cell insulin secretion. We demonstrated that
type 2 diabetes risk alleles are associated with decreased
ADCY5 expression in human islets and examined candi-
date variants for regulatory function. rs11708067 overlaps
a predicted enhancer region in pancreatic islets. The type
2 diabetes risk rs11708067-A allele showed fewer H3K27ac
ChIP-seq reads in human islets, lower transcriptional activ-
ity in reporter assays in rodent b-cells (rat 832/13 and
mouse MIN6), and increased nuclear protein binding com-
pared with the rs11708067-G allele. Homozygous deletion
of the orthologous enhancer region in 832/13 cells
resulted in a 64% reduction in expression level of Adcy5,
but not adjacent gene Sec22a, and a 39% reduction in
insulin secretion. Together, these data suggest that
rs11708067-A risk allele contributes to type 2 diabetes by
disrupting an islet enhancer, which results in reduced
ADCY5 expression and impaired insulin secretion.
Genome-wide association studies (GWAS) have identified more
than 80 loci associated with type 2 diabetes (1,2); however,
the underlying biological and molecular mechanisms respon-
sible for most of these associations remain unknown. One
type 2 diabetes association signal overlaps introns 1–3 of the
ADCY5 gene. The rs11717195-T and the rs11708067-A al-
leles were associated (P , 5 3 1028) with type 2 diabetes
risk in a GWAS meta-analysis of individuals of European
ancestry (3), and rs11717195-T was associated (P = 2.2 3
1028) with type 2 diabetes risk in a trans-ancestry GWAS
meta-analysis (4). The rs11708067-A allele was associated
(P = 9.1 3 1024) with type 2 diabetes risk in a candidate
variant study in individuals from South Asia (5) and in a
candidate gene study (P = 4.7 3 1023) in individuals of
African American ancestry (6). rs11717195 and rs11708067
exhibit strong linkage disequilibrium (LD) with each other
(r2 $0.938, 1000 Genomes phase 3) in individuals of Eu-
ropean, East Asian, and South Asian ancestry (7,8). In indi-
viduals of sub-Saharan African ancestry, rs143882978 (LD
r2 = 0.005 with rs11708067, 1000 Genomes phase 3 Af-
rican) was also associated (P = 0.02) with type 2 diabetes (9).
Variants at the ADCY5 locus are also associated with
other glycemic traits (Supplementary Table 1) that implicate
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them as variants affecting islet and b-cell function.
rs11708067-A was associated (P = 1.7 3 10214) with higher
fasting glucose levels in individuals of European ancestry
(10) and higher fasting glucose levels (P = 6.3 3 1026) in
individuals of African ancestry (11). An additional variant,
rs2877716, in strong LD (r2 = 0.837, 1000 Genomes phase 3
European [EUR]) (7) with rs11708067, was associated
(P = 4.2 3 10216) with 2-h glucose level (12). Associations
with fasting glucose, 2-h glucose, insulinogenic index, and
2-h insulin (rs9883204, n = 2,151, P# 0.05) have also been
reported in Asian Indians (13). ADCY5 variant alleles
associated with higher glucose levels were also associ-
ated with lower birth weight (rs9883204, LD r2 = 0.826
with rs11708067, 1000 Genomes phase 3 EUR, P , 5 3
1028) (14). The type 2 diabetes–, fasting glucose–, and 2-h
glucose–associated variant, rs11708067, was also associated
(P = 2.03 1023) with impaired proinsulin-to-insulin conver-
sion as individuals homozygous for the type 2 diabetes risk A
allele showed higher proinsulin levels and a higher proinsu-
lin/insulin ratio after an oral glucose tolerance test (15).
Transethnic fine-mapping studies (11) and credible set anal-
yses suggest rs11708067 is a functional variant at this locus.
ADCY5 encodes adenylate cyclase 5, which catalyzes gen-
eration of cyclic AMP (cAMP) from ATP (16). cAMP, ATP,
and calcium (Ca2+) regulate insulin secretion in the pancre-
atic islet b-cell (17). Previous studies have established
ADCY5 as a compelling candidate target gene influencing
glucose metabolism, showing association of the type 2 di-
abetes risk alleles with decreased ADCY5 mRNA expression
(18–20). Furthermore, ADCY5 knockdown in human islets
reduced glucose-stimulated cAMP levels, inhibiting glucose
metabolism toward ATP and glucose-stimulated insulin
secretion (18).
Identification of regulatory variants that exhibit allelic
differences at GWAS loci can help elucidate the molecu-
lar mechanism(s) responsible for the disease associations.
Open chromatin data in human pancreatic islets, from DNase
I hypersensitivity sequencing (DNase-seq) (21), formaldehyde-
assisted isolation of regulatory elements sequencing
(FAIRE-seq) (22), and assay for transposase-accessible chro-
matin with high-throughput sequencing (ATAC-seq) (20)
experiments, can help to identify regulatory elements of
genes that play a role in type 2 diabetes risk.
In this study, we aimed to identify the variant(s) and
molecular mechanism(s) responsible for the type 2 diabetes
and glycemic trait associations at the ADCY5 locus. We
demonstrate that 1 of 18 candidate variants at the locus,
rs11708067, exhibits allelic differences in reporter assays of
transcriptional activity in two insulinoma cell lines, consis-
tent with the direction of association between the type 2
diabetes risk alleles and expression of ADCY5. We present
evidence that the rs11708067-A type 2 diabetes risk allele
exhibits reduced enhancer potential (reduced representa-
tion in islet histone 3 lysine 27 acetylation [H3K27ac] chro-
matin immunoprecipitation sequencing [ChIP-seq] reads) in
vivo. Additionally, rs11708067-A is bound by different
transcription factor complexes in vitro. We also show that
the orthologous enhancer region in 832/13 cells reduces
Adcy5 expression and insulin secretion. Together, these data
provide a candidate molecular mechanism for the regulatory
function of genetic variation at this type 2 diabetes locus.
RESEARCH DESIGN AND METHODS
Association With Human Islet Gene Expression and
Additional Glycemic Traits
We evaluated evidence of association between type 2 di-
abetes and fasting glucose GWAS variants and gene
expression levels in human islets by analyzing existing
RNA-seq–based expression quantitative trait loci (eQTL)
data from 112 individuals (20,23). We looked up the
evidence of association between rs11708067 and gene
expression level for genes with a transcription start site
located within 1 Mb (Supplementary Fig. 1A and B). After
rs11708067, which is the variant most strongly associated
with ADCY5 expression level, no additional variant was
significant (false discovery rate [FDR] ,5%) in a stepwise
forward selection approach, as previously described (20).
The Genotype-Tissue Expression (GTEx) Project portal
was accessed to look for variant association with ADCY5
expression (www.gtexportal.org).
We also evaluated associations between rs11708067 and
21 glucose- and insulin-related traits from ;8,500 individ-
uals without diabetes from the Metabolic Syndrome in Men
(METSIM) study (Supplementary Table 2) (24,25). Trait
values containing skewed distributions were log transformed,
and we winsorized all traits at 5 SDs from the mean. We
adjusted all trait measurements for BMI, age, and age squared
and inverse-normalized the residuals prior to associa-
tion analyses (26). We assumed an additive genetic model
when testing for trait–variant associations and used a linear
mixed model to correct for relatedness, as applied in Efficient
Mixed-Model Association eXpedited (EMMAX) (27).
Identification of a Potential Transcriptional Enhancer
Region Overlapping rs11708067
We used LDlink (8) to identify variants in strong LD
(r2 .0.8) with rs11708067 in the 1000 Genomes Project
phase 3 EUR (7) data set. We used FAIRE-seq (22), DNase-
seq (21), chromatin states (28), and ATAC-seq data (20)
from human pancreatic islets to identify potential transcrip-
tional enhancer regions at ADCY5.
H3K27ac ChIP-seq in a Primary Human Islet Sample
We obtained human pancreatic islets through the In-
tegrated Islet Distribution Program (IIDP) in accordance
with regulations of human subject research. We performed
H3K27ac ChIP-seq experiments and read mapping as
previously described (21,28). We aligned sequence reads to
the UCSC Genome Browser build hg19 considering vari-
ants from the 1000 Genomes Project using GSNAP (29)
with AA-ALIGNER (30). When sequences were the same,
we aligned the five sequences with the highest overall
quality. We determined significance of allelic imbalance
at rs11708067 using an exact binomial test with a null
reactions using the LightShift Chemiluminescent EMSA Kit
(Thermo Fisher Scientific). We incubated binding buffer and
Poly(dI-dC) with 2–4 mg of 832/13 or MIN6 nuclear lysate
at room temperature for 10 min, and then added biotin-
labeled DNA probes. For competition reactions, we added
40- to 240-fold excess unlabeled double-stranded probe and
incubated the reactions for 10 min before adding the biotin-
labeled DNA. We then performed gel electrophoresis and
transfer, wash, and detection steps as described previ-
ously (32,33). For supershift assays, we added 4–8 mg of the
following antibodies to the nuclear lysate for 20 min be-
fore adding labeled DNA probes: CEBPA (sc-613), CEBPB
(sc-1503 and sc-79623), NKX2.2 (sc-150153), FOXA2
(sc-91873), PDX1 (sc-146623), p300 (sc-5853), NKX6.1
(sc-150303), MAFB (sc-228303), YY1 (sc-2813), RXRA
(sc-5533) antibodies (all from Santa Cruz Biotechnology,
Inc., Dallas, TX).
CRISPR-Cas9–Mediated Deletion of Adcy5 Enhancer
Element
We used BLAT (http://genome.ucsc.edu) to identify the hu-
man genome sequence of the enhancer region containing
rs11708067 (hg19) in the rat genome (rn5) and designed
guide RNA oligonucleotides to target the conserved en-
hancer region using CRISPR Design (http://crispr.mit.edu/).
Three guide RNAs upstream of rs11708067 were cloned
into a pSpCas9(BB)-2A-GFP (34) vector (PX458, a gift
from F. Zhang [Broad Institute of MIT and Harvard,
Cambridge, MA], Addgene plasmid #48138), and three guide
RNAs downstream of rs11708067 were cloned into a modified
PX458 vector containing an mCherry marker in place of
GFP. Target DNA sequences for guide RNAs are listed in
Supplementary Table 3 and were validated in each plasmid
by Sanger sequencing. We transfected three combinations
of guide RNA pair containing GFP and mCherry vectors into
832/13 cells using Lipofectamine 2000 (Thermo Fisher Sci-
entific), generating three deletions of the enhancer region
in the rat genome. We performed similar transfections us-
ing GFP and mCherry vectors lacking guide sequences to
generate GFP/mCherry empty vector control clones. After
incubating the 832/13 cells at 37°C with 5% CO2 for 72 h,
we selected single 832/13 cells positive for both GFP and
mCherry fluorescence by fluorescence-activated cell sorting
performed by the University of North Carolina at Chapel
Hill (UNC) Flow Cytometry Core Facility using the MoFlo
XDP sorter. We plated single GFP- and mCherry-positive
cells in each well and allowed the cells to grow for 21 days.
To validate homozygous deletions of the enhancer region, we
used QuickExtract (Epicentre, Madison, WI) to extract DNA
from clones, performed diagnostic PCR with primers span-
ning the targeted genomic enhancer region (listed in Supple-
mentary Table 3), and performed Sanger sequencing.
Evaluation of Adcy5 and Sec22a Gene Expression
We extracted RNA from CRISPR-Cas9–edited clones, GFP
and mCherry empty vector control clones, or untransfected
832/13 cells using the RNeasy Plus Mini kit (Qiagen,
expectation of 0.5, based  on  the number of reads  con-
taining the reference allele and the total number of 
reads at the heterozygous site.
Cell Culture
MIN6 mouse insulinoma b-cells (31) were grown in DMEM 
(Sigma-Aldrich, St. Louis, MO) with 10% FBS, 1 mmol/L 
sodium pyruvate, and 0.1 mmol/L b-mercaptoethanol. INS-
1–derived 832/13 rat insulinoma b-cells (a gift from 
C. Newgard, Duke University, Durham, NC) were grown in 
RPMI-1640 medium (Corning, NY) supplemented with 10%
FBS, 10 mmol/L HEPES, 2 mmol/L L-glutamine, 1 mmol/L 
sodium pyruvate, and 0.05 mmol/L b-mercaptoethanol. We 
maintained cell lines at 37°C and 5% CO2. We seeded MIN6 
or 832/13 cells (200,000 cells per well) in a 24-well plate 
1 day before transfections.
Transcriptional Reporter Assays
We PCR-amplified 231-base pair (bp) segments (centered 
around rs11708067) from the DNA of individuals homo-
zygous for each rs11708067 allele. Primers are listed in 
Supplementary Table 3. We cloned amplicons into the mul-
tiple cloning region of firefly luciferase reporter vector 
pGL4.23 (Promega, Fitchburg, WI) in both orientations 
with respect to the minimal promoter as described previ-
ously (32,33). We transfected three to five independent 
plasmids containing each allele in duplicate into MIN6 
mouse or 832/13 rat insulinoma cells. For transfection of 
MIN6 cells, we added 250 ng of plasmid DNA to each well 
with Lipofectamine LTX (Thermo Fisher Scientific, 
Waltham, MA) and Opti-MEM (Gibco, Waltham, MA). For 
transfection of 832/13 cells, we added 770 ng of plasmid 
to each well using Lipofectamine 2000 (Thermo Fisher Sci-
entific) and Opti-MEM (Gibco, Thermo Fisher Scientific). 
To control for transfection efficiency, we cotransfected 
phRL-TK Renilla luciferase reporter vector (Promega) with 
the pGL4.23 plasmids containing test sequences into MIN6 
and 832/13 cells (80 ng each well). Cells were incubated at 
37°C with 5% CO2 for 48 h. We performed luciferase assays 
with cell lysates using the Dual-Luciferase Reporter Assay 
System (Promega). We normalized firefly luciferase readings 
to Renilla luciferase readings and compared the readings to 
pGL4.23 minimal promoter empty vector control activity 
using unpaired two-sided t tests.
Electrophoretic Mobility Shift Assays
Complementary oligonucleotide probes (21 bp) cen-
tered on rs11708067 alleles (Supplementary Table 3) 
were synthesized by Integrated DNA Technologies, Inc.
(Coralville, IA) and labeled with biotin on the 59 end. We 
incubated single-stranded oligonucleotides in 10 mmol/L 
Tris, 50 mmol/L NaCl, 1 mmol/L EDTA, pH 8.0 at 95°C 
for 5 min followed by 70 1-min cycles with temperature 
decreasing by 1°C. We prepared nuclear lysates from MIN6 
cells and 832/13 cells using Pierce NE-PER Nuclear and 
Cytoplasmic Extraction Reagents (Thermo Fisher Scientific). 
We performed electrophoretic mobility shift assay (EMSA)
Hilden, Germany) from two independent experiments. We
plated 200,000 cells in 24-well plates, extracted RNA
after 24 h, and synthesized cDNA using the SuperScript
III First-Strand Synthesis System (Thermo Fisher Scientific).
We measured gene expression of Adcy5, Sec22a, and
B2m control by quantitative PCR using TaqMan assays
(Rn00575059_m1, Rn00589273_m1, Rn00560865_m1;
Applied Biosystems, Thermo Fisher Scientific) and the stan-
dard curve method. We generated standard curves using 1:3
serial dilutions of cDNA, measured in triplicate. We normal-
ized Adcy5 and Sec22a gene expression level to the mean
expression level of the control B2m gene. We plotted gene
expression for 832/13 cells, homozygous deletion clones,
and GFP/mCherry empty vector control clones as a percent-
age of the average gene expression measured for the con-
trol clones. We compared gene expression for intact control
clones with enhancer homozygous deletion clones using
unpaired t tests.
Insulin Secretion Assays
We plated 250,000 CRISPR-Cas9–edited, GFP/mCherry
empty vector control, and untransfected 832/13 cells into
24-well plates. We measured insulin secretion at 3 mmol/L
glucose and 18 mmol/L glucose concentrations 48 h after
plating or when cells were 90% confluent. We performed
insulin secretion assays on three separate occasions; on
each occasion, we measured insulin secretion for each sam-
ple in duplicate or triplicate using Rat Insulin ELISA
(Mercodia, Winston-Salem, NC). We compared insulin se-
cretion for intact control clones with enhancer homozygous
deletion clones using unpaired t tests.
RESULTS
rs11708067 Is Associated With ADCY5 Expression Level
in Primary Human Pancreatic Islets and With Glycemic
Traits in the METSIM Study
We examined evidence of association between the type 2
diabetes risk allele rs11708067-A and expression level of
nearby (,1 Mb) genes by evaluating islet eQTL data from
112 human pancreatic islet samples (20,23). rs11708067-A
allele was associated with decreased ADCY5 mRNA level
(P = 3.09 3 1029) (Supplementary Fig. 1A and B), consis-
tent with previous reports (18,19). The same lead variants
and LD proxies most strongly associated with type 2 diabe-
tes and glucose-related traits are most strongly associated
with ADCY5 mRNA level, strongly suggesting that these
signals are coincident. rs11708067 is not associated with
mRNA level (FDR.5%) of any other gene within 1 Mb. No
eQTL was observed in GTEx V6p at FDR #5% for other
tissues.
We evaluated the association between rs11708067 and
21 glycemic traits in ;8,500 Finnish males without diabe-
tes from the METSIM study. Among these traits, we ob-
served the strongest evidence of associations of the
rs11708067-A allele with three measures of plasma glu-
cose concentration after an oral glucose challenge: glucose
area under the curve between 30 min and 2 h (N = 8,591,
b = 0.086, P = 4.3 3 1025), glucose concentration after 2 h
(N = 8,620, b = 0.084, P = 5.8 3 1025), and glucose area
under the curve between 0 min and 2 h (N = 8,591, b =
0.083, P = 8.4 3 1025) (Supplementary Table 2).
rs11708067 Overlaps Evidence of Open Chromatin and a
Predicted Enhancer Region in Human Pancreatic Islets
We next aimed to determine whether the reported GWAS
lead variants or linked variants (proxies based on LD)
showed evidence of allelic differences in regulatory activity.
In 1000 Genomes phase 3 EUR data (7), 17 variants
exhibited strong LD (r2 .0.8) with any of the lead type 2
diabetes or glycemic trait lead GWAS variants (rs11708067,
rs11717195, rs2877716, rs9883204). Each of the 18 candi-
dates, including rs11708067, is located within ADCY5 in-
trons (Fig. 1). We used DNase-, FAIRE-, and ATAC-seq data
in primary human pancreatic islets to investigate poten-
tial regulatory regions overlapping variants at this locus
(20–22). Four of the 18 candidate variants overlap pre-
dicted enhancer regions (28) in human pancreatic islets
(Supplementary Table 4). Of these, rs11708067 overlaps
an ATAC-seq peak in pancreatic islets (20,35) and is the
only variant of the 18 to overlap both a DNase and FAIRE
peak in human pancreatic islets (Fig. 1 and Supplementary
Table 4).
Allelic Imbalance of H3K27ac Reads Overlapping
rs11708067 in Human Pancreatic Islets
Acetylation of H3K27ac marks active enhancer regions
(36,37). Thus, we evaluated H3K27ac ChIP-seq data in a
primary human islet sample heterozygous at rs11708067
and investigated the alleles in sequencing reads spanning
rs11708067. The H3K27ac ChIP-seq reads showed evidence
of allelic imbalance, with 9 reads containing rs11708067-A
reference allele compared with 69 reads containing the
rs11708067-G allele (Fig. 2) (exact binomial P = 1.2 3
10214). These data suggest that in the islet cellular chroma-
tin context, rs11708067 is located within an enhancer
region marked by H3K27ac.
rs11708067 Shows Allelic Differences in Enhancer
Activity
To investigate whether rs11708067 shows allelic differ-
ences in transcriptional regulatory activity, we tested a
231-bp DNA segment containing rs11708067 using lucif-
erase reporter assays in 832/13 rat insulinoma and MIN6
mouse cell lines. We examined each of the rs11708067
alleles in the sequence in both orientations with respect to a
minimal promoter. In 832/13 cells, we observed 1.6-fold
greater enhancer activity for the A allele compared with
empty vector control and 3.3-fold greater enhancer activity
for the G allele compared with an empty vector control in
the forward orientation, with significant differences be-
tween the alleles (Fig. 3A, P = 0.0007). In the reverse ori-
entation, we observed 0.84-fold luciferase activity (A allele)
compared with empty vector control and 1.3-fold enhancer
activity (G allele) compared with empty vector control, with
significant differences between the alleles (Fig. 3A, P =
0.003). In MIN6 cells, we observed 2.6-fold greater en-
hancer activity for the A allele compared with empty vector
control and 8.3-fold greater enhancer activity for the
G allele compared with empty vector control in the forward
orientation, with significant differences between the alleles
(Supplementary Fig. 2) (P = 1.9 3 1023). In the reverse
orientation, we observed 2.3-fold (A allele) and 13.9-fold
(G allele) greater enhancer activity compared with empty vec-
tor control with significant differences between the alleles
(Supplementary Fig. 2) (P = 4.9 3 1025). The lower tran-
scriptional activity of rs11708067-A is consistent with the
lower expression of rs11708067-A in the eQTL association
with ADCY5 in human islets. In both cell types and both
orientations, the rs11708067-G allele showed higher lucif-
erase activity, suggesting that rs11708067 can have an
allelic effect on transcriptional activity.
Alleles of rs11708067 Exhibit Differential Protein Binding
To determine whether transcription factors show allelic
differences in binding to DNA at rs11708067, we per-
formed EMSAs with 21-bp biotinylated probes containing
either the rs11708067-A or rs11708067-G alleles using
nuclear lysate from 832/13 or MIN6 cells. We observed four
bands with greater protein binding for the rs11708067-A
allele compared with the rs11708067-G allele (Fig. 3B, lane
Figure 1—rs11708067 overlaps pancreatic islet open chromatin and a strong enhancer chromatin state in ADCY5 intron 3. The 50-kb region
shown includes all 17 variants in strong LD (r2 >0.8, 1000 Genomes phase 3 EUR) with the type 2 diabetes–associated single nucleotide
polymorphism rs11708067 (in boldface type) (18 total noncoding candidate variants located within ADCY5 introns 1–3). Selected Encyclopedia
of DNA Elements (ENCODE) open chromatin (DNase, FAIRE) (21,22), chromatin accessibility (ATAC-seq) (20), and RNA-seq and chromatin state
tracks (28) are shown. The black vertical line above the pancreatic islet open chromatin tracks represents the 231-bp segment containing
rs11708067 that was tested in luciferase reporter assays. GM12878, lymphoblastoid cells from B cells; H1 ES, embryonic stem cells; HepG2,
human hepatocellular carcinoma cells; HMEC, human mammary epithelial cells; HSMM, human skeletal muscle myoblasts; HUVEC, human
umbilical vein endothelial cells; islets, pancreatic islets; K562, leukemia cell line; NHEK, epidermal keratinocytes; NHLF, lung fibroblasts.
2 vs. lane 7, and Supplementary Fig. 3B, lane 2 vs. lane 7).
Addition of unlabeled probe containing the A allele of
rs11708067 competed away the stronger A-allele bands
(Fig. 3B, lane 3, and Supplementary Fig. 3A and B, lanes
3). Using bioinformatic prediction tools JASPAR (38),
TRANSFAC (39,40), and The Islet Regulome Browser (41)
to search for transcription factor motif matches, we found
that the DNA region spanning rs11708067 overlaps a
NKX2.2 transcription factor ChIP-seq peak (41) and a pre-
dicted binding motif for CEBP. However, incubation of the
EMSA reaction with antibodies to CEBPB or NKX2.2 did
not result in supershifts (Fig. 3B, lanes 4 and 5, respectively,
and lanes 9 and 10, respectively; Supplementary Fig. 3B,
lanes 5 and 10). Additional antibodies we tested in EMSAs,
including FOXA2, PDX1, p300, NKX6.1, MAFB, YY1, and
RXRA, also did not demonstrate evidence of supershifts
(Supplementary Fig. 4). In summary, multiple undefined
proteins from both mouse and rat b-cell nuclear lysates
bind specifically to the A allele of rs11708067.
Deletion of the Enhancer Element Reduced Adcy5
Expression and Insulin Secretion
To investigate whether the enhancer element affects the
function of Adcy5 in 832/13 cells, we generated deletions of
the enhancer element using CRISPR-Cas9 technology. We
successfully generated three clones with homozygous dele-
tions of the enhancer element (Fig. 4A and Supplementary
Figs. 5–8) and measured expression of Adcy5 and nearby
gene Sec22a. Compared with five control clones with an
intact enhancer, the three clones harboring homozygous
Figure 2—Evidence of allelic imbalance in H3K27ac ChIP-seq reads at rs11708067. H3K27ac ChIP-seq reads in a primary human islet sample
heterozygous at rs11708067. Blue indicates reads that contain the G allele of rs11708067, red indicates reads that contain the A allele of
rs11708067, and gray indicates reads in the peak that do not overlap rs11708067.
Figure 3—rs11708067 exhibits allelic differences in transcriptional activity and protein binding in 832/13 rat insulinoma cells. A: The 231-bp
segments containing allele A or G of rs11708067 were cloned into a pGL4.23 luciferase reporter vector upstream of the minimal promoter in both
orientations (forward and reverse). The relative luciferase activities of plasmids transfected into 832/13 cells normalized to an empty vector
control are shown on the y-axis. Error bars represent SD of three to five independent clones per allele (t tests). Black triangles, empty vector;
black circles, rs11708067-A allele; white circles, rs11708067-G allele. B: EMSAs with biotin-labeled probes containing either the A or G allele of
rs11708067. Probes were incubated with 2.2 mg 832/13 rat insulinoma nuclear lysate. The arrows indicate differential protein binding to the A
allele, which is competed away by 240-fold excess competitor DNA containing the A allele (lane 3). EMSAs were performed six separate times
with consistent results. Antibodies to CEBPB and NKX2.2 (8 mg) were tested for supershifts in lanes 4 and 5, respectively, and lanes 9 and 10,
respectively.
deletions of the enhancer element exhibited no effect on
expression of Sec22a (Fig. 4B) (P = 0.52) but did show a
mean 64% reduction in Adcy5 expression (Fig. 4C) (P =
0.002). We then investigated whether deletion of the en-
hancer element led to effects on insulin secretion. The three
homozygous deletion-containing clones showed a mean
39% reduction of insulin secretion at basal 3 mmol/L glu-
cose concentration compared with the five control clones
(Fig. 4D, P = 0.0006; Supplementary Fig. 9). Effects on in-
sulin secretion after treatment with 18 mmol/L glucose
were variable (Supplementary Fig. 10). These results show
that the enhancer element containing rs11708067 affects
Adcy5 expression and furthermore can alter the role of
Adcy5 in insulin secretion.
DISCUSSION
Identification of the functional regulatory variants at GWAS
loci and the genes they regulate can help elucidate the
mechanisms by which variants alter gene function. In this
study, we showed evidence of a functional regulatory variant
at the ADCY5 GWAS for type 2 diabetes (3,4) and glycemic
traits (10–12,42). We confirmed that the type 2 diabetes
risk alleles are associated with lower expression of ADCY5 in
human pancreatic islets (18–20) and showed that candidate
variant rs11708067 exhibits allelic differences in regulatory
activity. Specifically, the rs11708067-A allele showed lower
transcriptional activity, stronger binding of nuclear pro-
teins, and lower enhancer activity in the native chromatin
context of human islets based on H3K27ac islet ChIP-seq
Figure 4—Deletion of the orthologous enhancer element in 832/13 cells leads to reduced Adcy5 expression and reduced insulin secretion.
A: Three homozygous deletions (indicated by the genomic regions in between the Xs) of the orthologous Adcy5 enhancer region were generated
using CRISPR-Cas9 technology in 832/13 rat insulinoma cells. UCSC Genome Browser chromosome 11 coordinates are shown for the rat
genome rn5. PhyloP Cons indicates basewise conservation with 13 species (rat, mouse, guinea pig, human, chimp, rhesus, cow, dog, panda,
opossum, chicken, turkey, and zebrafish) based on the phyloP track from the UCSC Genome Browser. Gene expression normalized to B2m
control (shown on the y-axes for B and C) or insulin secretion (shown on the y-axis for D) was measured in 832/13 rat b-cells. B: Normalized
Sec22a nearby control gene expression (displayed as a percent of average expression of intact control clones). C: Normalized Adcy5 expression
(displayed as a percent of average expression of intact control clones). D: Insulin secretion at 3 mmol/L glucose concentration (displayed as pg
insulin/mg total protein). B and C: For gene expression, error bars indicate the SD of three to five clones per sample for two independent
experiments. D: Insulin secretion assays were performed in duplicate or triplicate, and error bars indicate the SD of two to five clones per sample.
Unpaired t tests were performed to compare gene expression or insulin secretion of enhancer homozygous deletion clones with intact control
clones. Black circles, wild-type (WT) 832/13 clones; black triangles, intact control clones; white circles, enhancer homozygous deletion clones.
reads. Additionally, CRISPR-Cas9–mediated homozygous
deletion of the enhancer element in rat insulinoma cells
diminished Adcy5 gene expression and reduced insulin se-
cretion. We propose that the rs11708067-A allele binds to
one or more transcriptional repressor proteins and reduces
ADCY5 transcriptional activity, leading to reduced insulin
secretion and increased type 2 diabetes risk.
We provide evidence that rs11708067 is a regulatory
variant at the ADCY5 locus. Our data are consistent with
the fact that rs11708067 was the strongest candidate for
an effect on regulatory function based on its location in a
putative islet enhancer element. rs11708067 also showed
the highest posterior probability (highest log-Bayes factor
12.39) of driving the association signal from a credible
set analysis (11). Considering that some GWAS loci have
multiple functional regulatory variants responsible for the
association (43), other variants at this locus may also
contribute to allelic differences in transcriptional activity.
Despite evidence of a NKX2.2 ChIP-seq peak in human
pancreatic islets and a predicted binding motif for CEBP
overlapping rs11708067, we did not observe evidence of
supershifts using antibodies to NKX2.2 and CEBPB. These
factors may not bind to the sequence spanning rs11708067,
or overexpression of these proteins may be necessary to
elicit a supershift. The absence of a supershift may also be
attributed to taking the protein and DNA interactions out
of their genomic DNA and chromatin context.
ADCY5 is the strongest candidate gene underlying the
metabolic trait associations at this locus. ADCY5 is strongly
expressed in human pancreatic islets (18,44) and eQTL data
showed a strong coincident association between the GWAS
variant rs11708067 and ADCY5 expression in islets (19,20).
ADCY5 is also highly expressed in H1 human embryonic
stem cells (Fig. 1) (28), which may suggest a role for
ADCY5 expression in development, consistent with an as-
sociation between an ADCY5 variant and birth weight
(14,45). The fetal insulin hypothesis supports the reported
associations between the type 2 diabetes risk alleles and low
birth weight (46). This hypothesis suggests that genetic
variants contribute to decreased insulin secretion by
the fetus and/or decreased insulin sensitivity in fetal tis-
sues. Considering that insulin is a growth factor, these re-
ductions in insulin secretion and/or insulin sensitivity
ultimately lead to reduced fetal growth and birth weight
(47). ADCY5 may also act in other tissues that could con-
tribute to biological mechanisms of type 2 diabetes; for
example, alterations in TCF7L2 type 2 diabetes–associated
gene expression alter glucose and insulin metabolism in
liver and pancreatic islets (48–50).
Adenylate cyclase 5 has been shown to couple glucose
signals to cAMP production, increase Ca2+, and influence
b-cell connectivity (18). Our METSIM study trait associa-
tion data support a role for rs11708067 in glucose homeo-
stasis after a glucose stimulus (Supplementary Table 2).
However, in our experiments, deletion of the enhancer el-
ement decreased Adcy5 expression and showed lower insu-
lin secretion at basal (3 mmol/L) glucose concentration
(Fig. 4D and Supplementary Fig. 9), but we did not observe
consistent alterations in insulin secretion at 18 mmol/L
glucose (Supplementary Fig. 10). These contrasting results
may be attributed to our deletion of only a single regulatory
element, the variable responsiveness of 832/13 cells to glu-
cose stimulation, or that the deletion may not perfectly
represent the human regulatory element containing
rs11708067. Nonetheless, the effect of deleting the regula-
tory element on gene expression supports the role of this
noncoding sequence in the cellular genomic context.
Taken together, our data identify a functional variant at
the ADCY5 locus, rs11708067, and provide evidence of a
potential mechanism by which this variant affects expres-
sion of ADCY5, leading to altered fasting glucose levels and
risk of type 2 diabetes (Supplementary Fig. 11). The type 2
diabetes risk allele rs11708067-A is likely to bind multiple
repressor proteins that weaken enhancer activity and re-
duce ADCY5 expression. These experimental data provide
consistent evidence supporting the role of a noncoding var-
iant in the molecular basis of type 2 diabetes.
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